 | A major contributor to this article appears to have a close connection with its subject. (January 2017) |
 | |
| Company type | Public |
|---|---|
| Nasdaq: ANTH | |
| Industry | Pharmaceuticals |
| Founded | 2004 |
| Headquarters | Hayward, California, U.S. |
Key people | Craig Thompson (President and CEO) |
| Website | Anthera.com |
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase (Sollpura), Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency (EPI) is currently in Phase 3 clinical trials, and A-623 (Blisibimod) for the treatment of IgA nephropathy[1][2] is currently in Phase 2 clinical trial.
- ^ "Overview". Anthera Pharmaceuticals, Inc. Archived from the original on August 21, 2014. Retrieved August 11, 2014.
- ^ "Management Team". Anthera Pharmaceuticals, Inc. Archived from the original on August 12, 2014. Retrieved August 11, 2014.